Back to top

Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss

As previously reported, Guggenheim downgraded Sionna Therapeutics (SION) to Neutral from Buy and removed the firm’s prior price target after a stud...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Vertex Pharmaceuticals Incorporated (VRTX)